CADL - Candel Therapeutics

-

$undefined

N/A

(N/A)

Candel Therapeutics NasdaqGM:CADL Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the?enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Location: 117 Kendrick Street, Needham, MA, 02494, United States | Website: https://www.candeltx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

211.8M

Cash

92.17M

Avg Qtr Burn

-6.80M

Short % of Float

14.81%

Insider Ownership

20.83%

Institutional Own.

42.64%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CAN-2409 Details
Intermediate/high-risk Prostate cancer

Phase 3

Data readout

CAN-2409 Details
Cancer, Solid tumor/s, Low-to-intermediate-risk non-metastatic prostate cancer

Phase 2b

Update

CAN-2409 + Valacyclovir w/ ICI treatments Details
Lung cancer, Cancer, Solid tumor/s, III/IV Non-small cell lung carcinoma

Phase 2

Update

CAN-2409 + Valacyclovir w/ SoC Details
Pancreatic cancer, Cancer, Pancreatic ductal adenocarcinoma

Phase 2

Update

CAN-3110 Details
Solid tumor/s, Cancer, Glioma

Phase 1b

Data readout

CAN-2409 + Opdivo Details
Cancer, Glioma, Solid tumor/s

Failed

Discontinued